Paper40356972
Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases.
Wang T and 7 others. Front Pharmacol, 2025. Cited by 10 papers, by iCite.
Cite this record
ConductScience Library. Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases. Papers, record 40356972. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40356972
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References122
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33994347 | Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan. | Respir Investig | 2021 | https://conductscience.org/library/papers/33994347 | PubMed |
| 2 | 30364407 | Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study. | ERJ Open Res | 2018 | https://conductscience.org/library/papers/30364407 | PubMed |
| 3 | 37709326 | Strategies and interventions to strengthen pharmacovigilance systems in low-income and middle-income countries: a scoping review. | BMJ Open | 2023 | https://conductscience.org/library/papers/37709326 | PubMed |
| 4 | 28921394 | Combination Therapy with Pirfenidone plus Prednisolone Ameliorates Paraquat-Induced Pulmonary Fibrosis. | Inflammation | 2018 | https://conductscience.org/library/papers/28921394 | PubMed |
| 5 | 24836849 | Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. | Respirology | 2014 | https://conductscience.org/library/papers/24836849 | PubMed |
| 6 | 32297284 | Safety and Efficacy of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis: A Nationwide Post-Marketing Surveillance Study in Korean Patients. | Adv Ther | 2020 | https://conductscience.org/library/papers/32297284 | PubMed |
| 7 | 36585256 | Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone. | Eur Respir J | 2023 | https://conductscience.org/library/papers/36585256 | PubMed |
| 8 | 25651859 | Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis. | BMC Med | 2015 | https://conductscience.org/library/papers/25651859 | PubMed |
| 9 | 28091615 | Pirfenidone controls the feedback loop of the AT1R/p38 MAPK/renin-angiotensin system axis by regulating liver X receptor-α in myocardial infarction-induced cardiac fibrosis. | Sci Rep | 2017 | https://conductscience.org/library/papers/28091615 | PubMed |
| 10 | 39821007 | Real-world safety of maribavir: a retrospective study based on signal detection in the FDA adverse event reporting system. | Int J Clin Pharm | 2025 | https://conductscience.org/library/papers/39821007 | PubMed |
| 11 | 28883482 | Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis. | Sci Rep | 2017 | https://conductscience.org/library/papers/28883482 | PubMed |
| 12 | 28232409 | Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. | Eur Respir J | 2017 | https://conductscience.org/library/papers/28232409 | PubMed |
| 13 | 32664913 | Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study. | BMC Pulm Med | 2020 | https://conductscience.org/library/papers/32664913 | PubMed |
| 14 | 38434706 | Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38434706 | PubMed |
| 15 | 31016670 | Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. | Clin Pharmacokinet | 2019 | https://conductscience.org/library/papers/31016670 | PubMed |
| 16 | 38044938 | Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS). | Front Pharmacol | 2023 | https://conductscience.org/library/papers/38044938 | PubMed |
| 17 | 29101500 | Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres. | Clin Transl Med | 2017 | https://conductscience.org/library/papers/29101500 | PubMed |
| 18 | 18690886 | The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. | Curr Clin Pharmacol | 2008 | https://conductscience.org/library/papers/18690886 | PubMed |
| 19 | 27005406 | Pirfenidone-induced severe phototoxic reaction in a patient with idiopathic lung fibrosis. | J Eur Acad Dermatol Venereol | 2016 | https://conductscience.org/library/papers/27005406 | PubMed |
| 20 | 24836312 | A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. | N Engl J Med | 2014 | https://conductscience.org/library/papers/24836312 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42781927 | TRPML1 agonist ML-SA5 attenuates pulmonary fibroblast activation by suppressing mTOR and restoring autophagic flux. | FEBS Open Bio | 2026 | https://conductscience.org/library/papers/42781927 | PubMed |
| 42369125 | Comparative efficacy of different types of structured exercise interventions for idiopathic pulmonary fibrosis: a systematic review and meta-analysis. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42369125 | PubMed |
| 41995999 | Efficacy and tolerability of generic pirfenidone after switch from Esbriet® in idiopathic pulmonary fibrosis: a real-world observational study. | Intern Emerg Med | 2026 | https://conductscience.org/library/papers/41995999 | PubMed |
| 41891405 | Combination antifibrotic and immunosuppressive therapy in progressive fibrosing ILD. | Sarcoidosis Vasc Diffuse Lung Dis | 2026 | https://conductscience.org/library/papers/41891405 | PubMed |
| 41522097 | Adverse side-effects of antifibrotic drugs and outcome of treatment in idiopathic pulmonary fibrosis. | J Thorac Dis | 2025 | https://conductscience.org/library/papers/41522097 | PubMed |
| 41507413 | Rubiadin-1-methyl ether alleviates bleomycin induced pulmonary fibrosis. | Sci Rep | 2026 | https://conductscience.org/library/papers/41507413 | PubMed |
| 41132892 | Refractory Spontaneous Pneumothorax in Interstitial Lung Disease Under Pirfenidone Treatment. | Respirol Case Rep | 2025 | https://conductscience.org/library/papers/41132892 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40356972
GET https://conductscience.org/api/papers/v1/40356972/references?page=2